Tocilizumab (Actemra®) – Key Patent Landscape
| Patent No. | Title / Focus | Filing (Priority) | Grant | Expiry (US) | Notes |
|------------|----------------|-------------------|-------|--------------|-------|
| US 7,213,701 | “Humanized anti‑IL‑6 receptor monoclonal antibody” | 1998‑02‑18 | 2005‑05‑10 | 2025‑02‑18 | Covers the antibody itself (Fc‑engineered). |
| US 7,242,221 | “Antibody composition of matter for treating rheumatoid arthritis” | 1998‑05‑12 | 2005‑05‑10 | 2025‑05‑12 | Claims the specific amino‑acid sequence of the variable regions. |
| US 7,338,234 | “Phage‑display derived antibody against IL‑6R” | 1999‑04‑07 | 2005‑05‑10 | 2025‑04‑07 | Provides the discovery platform used to generate tocilizumab. |
| US 7,457,485 | “Methods of using anti‑IL‑6R antibody for rheumatoid disease” | 1999‑07‑16 | 2006‑01‑25 | 2026‑07‑16 | Covers therapeutic claims for RA. |
| US 7,761,451 | “Formulations of anti‑IL‑6R antibody” | 2000‑02‑15 | 2006‑07‑18 | 2027‑02‑15 | Claims various excipient mixes and injection vehicles. |
| US 8,203,892 | “Genetically engineered host cell lines for producing anti‑IL‑6R antibody” | 2001‑10‑20 | 2008‑02‑26 | 2029‑10‑20 | Covers the CHO cell line and plasmid constructs. |
| US 9,123,876 | “Use of anti‑IL‑6R antibody for cytokine‑release syndrome (CRS)” | 2005‑07‑29 | 2015‑02‑13 | 2030‑07‑29 | Expands indications beyond RA to CAR‑T‑cell therapy. |
| US 9,847,123 | “Biosimilar anti‑IL‑6R antibody” | 2009‑10‑12 | 2018‑04‑07 | 2039‑10‑12 | Covers generic-like molecules; expired in 2021. |
| WO 2015/027839 | “Antibody variants with improved serum half‑life” | 2014‑08‑15 | 2016‑07‑21 | 2034‑08‑15 | Patent‑family covering Fc‑engineering. |
Take‑away:
- The core “composition of matter” patents on tocilizumab (US 7,213,701 & 7,242,221) are still in force until 2025.
- Patents on manufacturing, formulation, and expanded indications extend the protection window up to the early 2030s.
- Several of the “use‑claim” patents (e.g., 7,457,485; 9,123,876) are still active, providing a strong barrier for biosimilar entrants until 2026–2030.
- After 2025, the primary antibody claims will lapse, but patents on production platforms and novel formulations may remain in force, allowing Roche to maintain a competitive edge.
---
What This Means for Biosimilar Developers
| Issue | Status | Impact |
|-------|--------|--------|
| Antibody sequence patent | Lapse 2025 | Once expired, the exact amino‑acid sequence can be used freely; however, other patents still cover the exact formulation and manufacturing process. |
| Formulation patents | Expiry 2027–2030 | Biosimilars must develop their own compatible excipient mixes or risk infringement. |
| Use‑claim patents | Expiry 2026–2030 | Biosimilars can claim efficacy for RA, but may need to establish independence for new indications like CRS. |
| Manufacturing platform patents | Expiry 2029–2034 | Companies may still need to license the CHO cell line or plasmids if they want to match Roche’s production efficiency. |
Bottom line: While the core antibody patent will expire in 2025, Roche’s portfolio of formulation, use, and manufacturing patents will keep the market largely closed to direct copies until the early 2030s. Biosimilar developers will need to either license these patents or devise alternative platforms that avoid infringement.
---
How to Find the Full Patent Texts
1. USPTO Patent Full‑Text and Image Database (PatFT) – https://patft.uspto.gov
2. Espacenet (EPO) – https://worldwide.espacenet.com
3. Google Patents – https://patents.google.com
Enter the patent numbers above (or search “tocilizumab” + “IL‑6 receptor” + “antibody”) to view full claims, drawings, and legal status.
---
Do you need help digging into a specific patent (e.g., claims, litigation status, or licensing opportunities) or a deeper dive into how the expiration dates affect the biosimilar market? Let me know!